Peptide Library

A small-molecule angiotensin IV analogue (N-hexanoic-Tyr-Ile-(6) amino-hexanoic amide). Enhances hepatocyte growth factor (HGF) signalling and promotes synaptogenesis. Reported to be ~10 million times more potent than BDNF in some assays. Limited human data.

A synthetic analog of the immunomodulatory peptide tuftsin. Reduces anxiety through GABA modulation, enhances cognitive function, and stabilizes mood without sedation. Developed alongside Semax at the Institute of Molecular Genetics in Moscow.

A synthetic analog of ACTH(4-10) developed in Russia. Upregulates BDNF (brain-derived neurotrophic factor), enhances dopamine and serotonin metabolism, and improves focus, memory, and cognitive performance without stimulant side effects.

Modified fragment of growth hormone (residues 177-191) developed for fat-loss applications. Mimics the lipolytic action of full-length GH without affecting blood glucose or IGF-1. Approved as a complementary medicine in Australia (TGA).

A synthetic growth-hormone-releasing hormone (GHRH) analogue. Two variants: with DAC (Drug Affinity Complex), half-life ~8 days; without DAC, half-life ~30 minutes. Stimulates pituitary GH release, raising IGF-1 and supporting recovery, body composition, and sleep.

A pentapeptide selective ghrelin receptor agonist. Stimulates pulsatile GH release without spiking cortisol or prolactin (unlike GHRP-2 and GHRP-6). Used most often stacked with CJC-1295 for synergistic GH amplification.

A decapeptide encoded by the KISS1 gene. The most potent known stimulator of GnRH release. Used in fertility research, hormone-axis recovery, and as a probe of HPG-axis function.

Tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-melanocyte-stimulating hormone. Inhibits NF-kB pathway and reduces pro-inflammatory cytokine signalling. Active orally with intact absorption (unlike most peptides). Strong evidence in IBD/colitis models.

A 28-amino-acid peptide hormone. Modulates T-cell function, dendritic cell activity, and Th1/Th2 balance. Approved as a pharmaceutical (Zadaxin) in 35+ countries for chronic hepatitis B/C, immune deficiency, and cancer adjunct therapy.

A 16-amino-acid mitochondrial-derived peptide. Activates AMPK signalling, improves insulin sensitivity, and enhances metabolic flexibility. Endogenous expression rises with exercise; declines with age.

Body Protection Compound-157 is a synthetic peptide derived from human gastric juice. It promotes angiogenesis, upregulates growth hormone receptors, and accelerates tendon, ligament, and gut healing through nitric oxide and FAK-paxillin pathway modulation.

A copper-binding tripeptide (Glycyl-L-Histidyl-L-Lysine bound to Cu(II)). Modulates gene expression to stimulate collagen, elastin, and stem-cell activation. Active topically and via injection. Endogenous levels decline ~60% by age 60.

Thymosin Beta-4 fragment that promotes cell migration, angiogenesis, and reduces inflammation systemically. Unlike BPC-157 which works locally, TB-500 travels through the bloodstream to reach injured tissue throughout the body.

Delta-sleep-inducing peptide. A nonapeptide that crosses the blood-brain barrier. Modulates HPA-axis activity and increases delta-wave (slow-wave) sleep architecture. Also studied for stress resilience and chronic pain.